HDT Bio
HDT Bio is a Seattle-area biotech startup developing an RNA-based COVID-19 vaccine candidate that self-assembles RNA onto nanoparticles.
Facts
- Sectors
- Biotech, Vaccines, RNA therapeutics
- Founded
- 2017 Seattle business license
- Type
- Corporation Seattle business license
- Registered name
- HDT Bio Corp Seattle business license
- Stage
- startup
Recent coverage
Front-page news, podcasts and videos about HDT Bio
Seattle Biotech Myosana Raises $5M to Develop Advanced Gene Therapy for Duchenne Muscular Dystrophy
Myosana Therapeutics, a Seattle biotech co-founded by University of Washington researchers, raised $5 million to advance a novel gene therapy candidate targeting Duchenne muscular dystrophy (DMD). The company aims to develop a gene delivery platform that can handle larger DNA segments compared to current standard methods, potentially improving treatment options against DMD.
